文献速递血液净化与透析

增量式与常规启动血液透析对残余肾功能影响的多中心可行性随机对照试验

A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function.
PubMed 文献 · Kidney Int · 2021-08-19

英国四中心纳入55例尿素清除率≥3 ml/min/1.73 m2的初治血透患者,随机分为增量式(每周两次,按残余肾功能调整剂量)或标准(每周三次)透析12个月。主要结局为可行性参数及6个月残余肾功能下降速率组间效应量,增量组严重不良事件发生率更低(IRR 0.47),但残余肾功能或生活质量无获益信号,增量透析成本更低。

要点

  • 增量式血透在残余肾功能充足的初治患者中安全可行,严重不良事件更少。
  • 增量组血清碳酸氢盐显著更低,可能需补充碱剂。
  • 增量透析未显示保护残余肾功能或改善生活质量的获益信号。

核心结论

  • 增量式血透在残余肾功能充足的初治患者中安全且节省成本,值得开展确证性试验。

研究设计与样本

  • 多中心可行性随机对照试验,英国四中心纳入55例尿素清除率≥3 ml/min/1.73 m2的初治血透患者,随机分为标准或增量方案12个月。

主要发现

  • 12个月时增量组21例、标准组12例仍在研究中,尿素清除率斜率无组间差异。
  • 增量组血清碳酸氢盐显著更低。
  • 两组血压、细胞外液及患者报告结局相似,各死亡3例。

关键数值与推荐

  • 增量式血透为每周两次,随残余肾功能丢失上调剂量,维持总(透析+肾脏)Std Kt/V>2。
  • 标准血透为每周三次、每次3.5-4小时,最低透析Std Kt/V为2。
  • 约三分之一患者符合入选标准,半数同意随机化。

临床怎么用

  • 对残余肾功能充足的初治患者可考虑增量式血透以降低严重不良事件和成本。
  • 增量透析期间需监测血清碳酸氢盐,必要时补充碱剂。

局限性

  • 可行性试验样本量小,主要结局为可行性参数,残余肾功能保护结论需确证性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Twice-weekly hemodialysis, as part of incremental initiation, has reported benefits including preservation of residual kidney function (RKF). To explore this, we initiated a randomized controlled feasibility trial examining 55 incident hemodialysis patients with urea clearance of 3 ml/min/1.73 m2 or more across four centers in the United Kingdom randomized to standard or incremental schedules for 12 months. Incremental hemodialysis involved twice-weekly sessions, upwardly adjusting hemodialysis dose as RKF was lost, maintaining total (Dialysis+Renal) Std Kt/V above 2. Standard hemodialysis was thrice weekly for 3.5-4 hours, minimum Dialysis Std Kt/V of 2. Primary outcomes were feasibility parameters and effect size of group differences in rate of loss of RKF at six months. Health care cost impact and patient-reported outcomes were explored. Around one-third of patients met eligibility criteria. Half agreed to randomization; 26 received standard hemodialysis and 29 incremental. At 12 months, 21 incremental patients remained in the study vs 12 in the standard arm with no group differences in the urea clearance slope. Ninety-two percent of incremental and 75% of standard arm patients had a urea clearance of 2 ml/min/1.73 m2 or more at six months. Serious adverse events were less frequent in incremental patients (Incidence Rate Ratio 0.47, confidence interval 0.27-0.81). Serum bicarbonate was significantly lower in incremental patients indicating supplementation may be required. There were three deaths in each arm. Blood pressure, extracellular fluid and patient-reported outcomes were similar. There was no signal of benefit of incremental hemodialysis in terms of protection of RKF or Quality of Life score. Median incremental hemodialysis costs were significantly lower compared to standard hemodialysis. Thus, incremental hemodialysis appears safe and cost-saving in incident patients with adequate RKF, justifying a definitive trial.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Vilar E, Kaja Kamal RM, Fotheringham J, et al. A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function. Kidney Int. 2021. PMID: 34418414. doi:10.1016/j.kint.2021.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。